This week, a number of domestic blockbuster drugs were approved for listing

The approval of the listing of drugs is of great significance to a company.
It can not only further enrich the company's product structure and enhance the company's market competitiveness, but also have a positive impact on the company's performance
.
In recent years, under the general trend of innovation in the pharmaceutical industry, it is obvious that more and more innovative drugs and blockbuster generic drugs have begun to accelerate their clinical approval and listing
.
According to statistics, as of October 20, there have been more than 25 new drugs on the market this year, of which 22 new drugs in category 1 (excluding vaccines and new indications), 21 new domestic drugs and 2 proprietary Chinese medicines
.
It is worth noting that this week, a number of pharmaceutical companies announced that new drugs have been approved for the market, bringing more medication options to a large number of patients
.
On November 19, the drug approval information on the NMPA website showed that the 4 types of generic sildenafil citrate tablets of Nanjing Hailing Pharmaceutical Group of Yangtze River Pharmaceutical Group were approved for marketing and reviewed
.
It is reported that sildenafil citrate tablets are indicated for erectile dysfunction and are a selective inhibitor of phosphodiesterase type 5 (PDE5)
.
In October 2014, the drug was officially launched in China
.
At present, in physical pharmacies in Chinese cities, sildenafil citrate tablets exceeded 2 billion yuan in 2017 and is expected to reach 2.
9 billion yuan in 2021
.
At present, the manufacturers of sildenafil citrate tablets listed in China also include Pfizer Pharmaceutical Co.
, Ltd.
, Jiangsu Yabang Epson Pharmaceutical Co.
, Ltd.
, Chengdu Diao Pharmaceutical Group Co.
, Ltd.
, and Changshan Biochemical Pharmaceutical (Jiangsu) Ltd.
, Ji Lin Jinheng pharmaceutical Co.
, Ltd.
and so on
.
The industry believes that with the approval of the four types of imitations of Sildenafil Citrate Tablets from Nanjing Hailing Pharmaceutical of Yangtze River Pharmaceutical Group, the market competition in this field will further intensify in the future
.
On November 16, Osaikang also issued an announcement stating that its wholly-owned subsidiary, Jiangsu Osaikang Pharmaceutical Co.
, Ltd.
, had recently received the "Notice of Acceptance" for the registration and marketing authorization application for domestic production of ASK120067 tablets issued by the National Medical Products Administration.

.
It is reported that ASK120067 is a third-generation oral third-generation EGFR with independent intellectual property rights, new molecular entities, and significant activity jointly developed by Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, and Jiangsu Aosaikang Pharmaceutical Co.
, Ltd.
TKI
.
It is worth noting that the current domestic competition for three generations of EGFR inhibitors has also been quite fierce
.
The first three third-generation EGFR-TKIs, osimertinib, ametinib and vometinib, have been negotiated and entered the medical insurance category B list.
vometinib has also participated in the negotiation this year.
According to public information, it is speculated There is a high probability of getting in
.
In addition, Befortinib from Betta Pharmaceuticals/Yifang Biologics, Rezetinib from Beierda Pharmaceuticals/Shipharm Group, and ASK120067 from Osaikang have been declared for listing, as well as Zhengda Fenghai, Runxin Biology, The third-generation EGFR inhibitors of Shenghe Pharmaceutical and other companies have also entered the late clinical stage
.
In general, with the support of a series of policies such as accelerated drug approval, patent protection, and tax reduction, the development of new drugs by pharmaceutical companies is heating up.
The industry predicts that some early-stage R&D and innovation companies will gradually enter the harvest period in the future
.